TABLE 2.
Treatment of patients in first, second, third and fourth line (L1, L2, L3, L4)
| Treatment | 1st line (N = 49) | 2nd line (N = 49) | 3rd line (N = 44) | 4th line (N = 16) |
|---|---|---|---|---|
| Purine nucleoside analogues | 25 (51%) | 34 (69%) | 29 (66%) | 9 (56%) |
| Cladribine | 20 (41%) | 22 (45%) | 12 (27%) | 6 (38%) |
| Pentostatin | 5 (10%) | 12 (24%) | 17 (39%) | 3 (19%) |
| Others | 15 (34%) | 7(44%) | ||
| Splenectomy | 3 (6%) | 1 (2%) | ||
| Rituximab | ‐ | 5 (10%) | 5 (11%) | 2 (13%) |
| Interferon α | 22 (45%) | 10 (20%) | 3 (7%) | 3 (19%) |
| Rituximab + cladribine | 4 (9%) | ‐ | ||
| Rituximab + Pentostatin | 1 (2%) | 1 (6%) | ||
| Cladribine + interferon α | 1 (2%) | ‐ | ||
| Rituximab + interferon α | ‐ | 1 (6%) | ||
| Rituximab + bendamustine then vemurafenib | 1 (2%) | ‐ | ||
| Untreated | 5 (10%) | ‐ |
Note: Results are presented as N (%).